You are right. MABT is Mid Atlantic BioTherapeutics, a partner with CUBT.
The CEO put up a message on his LinkedIn page
Mid-Atlantic BioTherapeutics (MABT)
424 followers
1. We need vaccines that can be delivered cheaply and effectively everywhere on earth to developed and undeveloped nations; if everyone isn’t vaccinated, we aren’t protected.
2. We need to make better vaccines for special populations, such as those with kidney failure, who are poorly responsive to the current vaccines.
3. We need to make better vaccines that will protect against the current and even future viral variants.
In collaboration with our partner, Curative Biotech, we continue to advance our COVID-19 vaccine that contains our proprietary IMT504 adjuvant.
Curative Biotech and Mid-Atlantic BioTherapeutics have agreed to develop a next generation COVID-19 vaccine targeted to meet the needs of this vulnerable population. A consequence of kidney failure in general is the loss of a robust immunologic response to infections, including COVID-19. This means that kidney failure patients may get a more severe version of COVID-19 that could lead to a greater chance of hospitalization or even death.
Dr. David Horn, CEO of Mid-Atlantic BioTherapeutics, added: “It is well known that kidney transplant recipients have impaired responses to mRNA COVID-19 vaccines. Recent data from France reveals that, even after 4 vaccine shots, many kidney transplant recipients have poor responses. In addition, kidney failure patients on dialysis do not initially respond as well to current vaccines and rapidly lose measurable antibodies when compared to the general population.”
As previously announced, Curative Biotech has acquired the worldwide rights for the development of IMT504 to treat symptomatic rabies. Curative Biotech and MABT are already working together to develop IMT504 to treat patients whose disease has advanced to a stage where the virus has migrated to the brain, causing lethal rabies encephalitis. There are currently no treatment options for these patients.
IMT504 has already been granted orphan drug designation in the US for the treatment of rabies, which may provide significant benefits including tax credits, market exclusivity and the waiver of certain FDA fees. Rabies is one of only a limited number of diseases which qualify for the FDA Tropical Disease Priority Review Voucher (PRV) Program that is granted to sponsors of approved tropical disease product applications that meet certain criteria. Once the sponsor obtains a PRV, the voucher can be used to obtain priority review designation for a subsequent application that does not itself qualify for priority review as described in the guidance, and it can be sold to another party.
Market Data 
Markets 
AI
